News stories about Catalent (NYSE:CTLT) have trended somewhat positive this week, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Catalent earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media coverage about the company an impact score of 44.893886380825 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:

Shares of Catalent (CTLT) traded up $0.04 during trading hours on Thursday, hitting $40.06. The stock had a trading volume of 887,052 shares, compared to its average volume of 908,550. The company has a quick ratio of 2.49, a current ratio of 2.91 and a debt-to-equity ratio of 2.01. The company has a market capitalization of $5,320.00, a PE ratio of 27.65, a P/E/G ratio of 2.54 and a beta of 1.41. Catalent has a 52-week low of $25.51 and a 52-week high of $43.39.

Catalent (NYSE:CTLT) last posted its earnings results on Monday, November 6th. The company reported $0.21 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.01. The company had revenue of $543.90 million for the quarter, compared to analysts’ expectations of $490.75 million. Catalent had a return on equity of 23.97% and a net margin of 5.01%. Catalent’s quarterly revenue was up 23.0% on a year-over-year basis. During the same period last year, the firm earned $0.16 earnings per share. research analysts expect that Catalent will post 1.46 EPS for the current fiscal year.

A number of research analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Catalent in a research note on Monday, October 23rd. Zacks Investment Research cut Catalent from a “buy” rating to a “hold” rating in a research note on Friday, November 3rd. BidaskClub raised Catalent from a “hold” rating to a “buy” rating in a research note on Thursday, October 5th. ValuEngine raised Catalent from a “hold” rating to a “buy” rating in a research note on Thursday, September 7th. Finally, Piper Jaffray Companies raised their price objective on Catalent from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Tuesday, November 7th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Catalent has a consensus rating of “Buy” and an average target price of $44.44.

In related news, insider John R. Chiminski sold 181,458 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Uwe Roehrhoff bought 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 21st. The stock was acquired at an average cost of $39.22 per share, for a total transaction of $294,150.00. The disclosure for this purchase can be found here. 1.70% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This article was posted by Watch List News and is owned by of Watch List News. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with's FREE daily email newsletter.